Publications by authors named "Zoltan Mueller"
Article Synopsis
- Bidirectional communication between neurons and glial cells is essential for proper brain function, but the effects of sudden changes in neuronal activity on these interactions are not well understood.
- In this study, researchers used a technique called DREADD to manipulate specific neuron populations in mouse brains, discovering that activating neurons leads to reduced synaptic density and increased glial cell reactivity, while silencing them has the opposite effect.
- The findings highlight rapid and dynamic interactions between neurons and glial cells that are influenced by neuronal activity, contributing to our understanding of brain function and potential implications for neurological conditions.
Background: Acquired or genetic abnormalities of the complement alternative pathway are the primary cause of C3glomerulopathy(C3G) but may occur in immune-complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) as well. Less is known about the presence and role of C4nephritic factor(C4NeF) which may stabilize the classical pathway C3-convertase. Our aim was to examine the presence of C4NeF and its connection with clinical features and with other pathogenic factors.
View Article and Find Full Text PDFBackground: Serelaxin is a recombinant form of human relaxin-2, a vasodilator hormone that contributes to cardiovascular and renal adaptations during pregnancy. Previous studies have suggested that treatment with serelaxin may result in relief of symptoms and in better outcomes in patients with acute heart failure.
Methods: In this multicenter, double-blind, placebo-controlled, event-driven trial, we enrolled patients who were hospitalized for acute heart failure and had dyspnea, vascular congestion on chest radiography, increased plasma concentrations of natriuretic peptides, mild-to-moderate renal insufficiency, and a systolic blood pressure of at least 125 mm Hg, and we randomly assigned them within 16 hours after presentation to receive either a 48-hour intravenous infusion of serelaxin (30 μg per kilogram of body weight per day) or placebo, in addition to standard care.